Clinical data has shown that treatment with B-RAF inhibitor vemurafenib resulted in tumor shrinkage and median progression-free survival for greater than six months in patients with B-RAF V600E mutated melanoma [25]. The gene discussed is BRAF; the disease is neoplasm.